Title of article
An update on allopurinol and kidney failure; new trend for an old drug
Author/Authors
Alirezaei, Amirhesam Clinical Research and Development Center at Shahid Modarres Hospital - Department of Nephrology - Shahid Beheshti University of Medical Sciences , Argani, Hassan Clinical Research and Development Center at Shahid Modarres Hospital - Department of Nephrology - Shahid Beheshti University of Medical Sciences , Asgharpour, Masoumeh Department of Nephrology - Rouhani Hospital of Medical Sciences, Babol, Iran , Bahadorimonfared, Ayad Department of Health & Community Medicine - Faculty of Medicine - Shahid Beheshti University of Medical Sciences , Bakhtiyari, Mahmood Department of Community Medicine - School of Medicine - Alborz University of Medical Sciences, Karaj, Iran
Pages
6
From page
297
To page
302
Abstract
Allopurinol is an inhibitor of xanthine oxidase (XO) enzyme. This drug is a reducer of uric acid in the body and one of the golden drugs with worldwide administration. XO is an important biological source of free radical generation. Allopurinol as an antioxidant, has direct and indirect antioxidant activity on these free radicals such as hydroxyl radical and superoxide anion. The purpose of this paper is to determine the impact of allopurinol on some aspects of renal disturbances such as renal ischemia/reperfusion injury (IRI), nephrotoxicity and contrast-induced nephropathy (CIN).
Keywords
Allopurinol , Free radicals , Hyperuricemia , Renal ischemia
Journal title
Journal of Renal Injury Prevention
Serial Year
2017
Journal title
Journal of Renal Injury Prevention
Record number
2435020
Link To Document